| Indikation | Kurzbezeichnung | EudraCT-Nr. | Phase | Titel | Studie aktiv? Ja/nein |
|---|---|---|---|---|---|
| ALL | GMALL-MOLACT1-BLINA Blast Successor Trial | 2015-000733-76 | II | A confirmatory multicenter, single-arm study to assess the efficacy, safety, and tolerability of the BITE ® antibody blinatumomab in adult patients with minimal residual disease (MRD) of B-precursor acute lymphoblastic leukemia (Blast Successor Trial) | ja |
| ALL | GMALL-INITIAL-1 | 2016-004836-39 | II | An open label phase II study to evaluate the efficacy and safety of inotuzumab ozogamicin for induction therapy followed by a conventional chemotherapy based consolidation and maintenance therapy in patients aged 56 years and older with acute lymphoblastic leukemia (ALL) | ja |
| ALL | GMALL 08/2013 | 2013-003466-13 | IV | Therapieoptimierung bei erwachsenen Patienten mit neu diagnostizierter akuter lymphatischer Leukämie (ALL) oder lymphoblastischem Lymphom (LBL) durch individualisierte, gezielte und intensivierte Therapie | ja |
| ALL | ALL-Register | ohne | ohne | GMALL ALL-Register | ja |
| AML | SORAML | 2008-004968-40 | II | A double-blind, placebo-controlled, randomized, multi-center phase-II trial to assess the efficacy of Sorafenib added to standard primary therapy in adult newly diagnosed AML patients ≤ 60 years | ja |
| AML | Shape | 2019-004536-37 | II | Treatment of MDS / AML patiens with an impending Hematological relapse with Azaci-tidine alone or in combination with PEvonedistat – a randomized phase 2 trial | ja |
| AML | ETAL3-ASAP | 2014-003124-44 | III | Evaluation of the impact of remission induction chemotherapy prior to allogeneic stemm cell transplantation in relapsed and poor-response patients with AML | ja |
| AML | ETAL-1 | 2010-019377-15 | Randomisierte Studie zur allogenen hämatopoetischen Stammzelltransplantation im Vergleich zur Standardchemotherapie bei Patienten in erster kompletter Remission im Alter von ≤60 Jahren mit AML intermediärem Risiko (Standardrisiko) und passendem Geschwister- oder Fremdspender | ja | |
| AML | EORTC No. 1301 | 2014-001486-27 | III | 10-day decitabine versus conventional chemotherapy ("3+7") followed by allografting in AML patients ≥ 60 years: a randomized phase III study of the EORTC Leukemia Group, CELG, GIMEMA and German MDS Group | ja |
| AML | DELTA-1 | 2014-003150-13 | II | A randomized placebo-controlled phase 2 study of Decitabine with or without Eltrombopag in AML patients ≥65 years of age | ja |
| AML | CPKC412A2301 | 2006-006852-37 | III | A phase III randomized, double blind study of induction (daunorubicin/cytarabine) and consolidation (high dose cytarabine) chemotherapy + midostaurin (PKC412) or placebo in newly diagnosed patients <60 years of age with FLT3 mutated Acute Myeloid Leukemia | ja |
| AML | BLAST | 2014-002702-21 | II | A double-blind, placebo controlled, randomized, multicenter, Phase II study to assess the efficacy of BL-8040 Addition to consolidation therapy in AML patients | ja |
| AML | ARO-013 | 2017-001600-29 | III | Phase III, Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy of the Addition of Crnolanib to Salvage Chemotherapy Versus Salvage Chemotherapy Alone in Subjects ≤ 75 Years of Age with Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia | ja |
| AML | AML-Register | n/a | ohne | AML-Register und Biomaterialdatenbank der Studienallianz Leukämie (SAL) | ja |
| AML | AG-221-AML-004 IDHENTIFY | 2015-000344-42 | III | A phase 3, multicenter, open-label, randomized study comparing the efficacy and safety of AG-221 (CC-90007) versus conventional care regimens in older subjects with late stage acute myeloid leukemia harboring an isocitrate dehydrogenase 2 mutation | ja |
| AML | AG120-C-009 | 2016-004907-30 | III | A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy | ja |
| AML | AC220-A-U302 QuANTUM-First | 2015-004856-24 | III | A Phase 3, Double-Blind, Placebo-controlled Study of Quizartinib (AC220) in Combination with Induction and Consolidation Chemotherapy, and Maintenance Therapy in Patients 18 to 70 Years Old with Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia | ja |
| AML | 2DAUNO (DaunoDouble) | 2013-003191-12 | III | Randomized comparison between two dose levels of daunorobicin and between one versus two cycles of induction therapy for adult patients with acute myeloid leukemia ≤ 60 years | Ja |
| AML / MDS | RELA02 RELAZA2 | 2010-022388-37 | II | Behandlung des drohenden hämatologischen Rezidivs von Patienten mit MDS oder AML mit 5-Azacytidin (Vidaza®) (RELAZ002-Studie): Eine prospektive, offene, einarmige, multizentrische Phase II Studie | ja |
| AML / MDS | PALOMA | 2018-002430-21 | II | Primary comparison of liposomal Anthracycline based treatment versus conventional care strategies before allogeneic cell transplantation in patients with higher risk MDS and oligoblastic AML - the PALOMA study | ja |
| Anämie | MOM-M281-006 | 2019-000720-17 | II/III | Efficacy and Safety of M281 in Adults with Warm Autoimmune Hemolytic Anemia: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study with a Long-term Open-label Extension | ja |
| Anämie | EMAA 9345 | 2014-000174-19 | II/III | Efficacy and Safety of Eltrombopag in Patients with Acquired Moderate Aplastic Anemia (EMAA) who are treated with Ciclosporin A. Prospective Randomized Multicenter Study comparing Thrombopoetin-Receptor agonist Eltrombopag (Revolade ®, GlaxoSmithKline) with Placebo in Patients with Acquired Moderate Aplastic Anemia who are treated with Ciclosporin A | ja |
| Anämie | CSEG101A2301 | 2017-001746-10 | III | A phase III, Multicenter, Randomized, Double-blind Study to Assess Efficacy and Safety of Two Doses of Crizanlizumab versus Placebo, wth or without Hydroxyurea/Hydroxycabamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Vaso-Occlusive Crisis (STAND) | ja |
| Anämie | C-935788-057 | 2018-004774-97 | III | A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fastamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia | ja |
| APL | NAPOLEON-Register | ohne | National Acute Promyelocytic Leukemia (APL) Observational Study Napoleon-Registry of the German AML-Intergroup | ja | |
| APL | APOLLO | 2015-001151-68 | III | A randomized Phase III study to compare arsenic trioxide (ATO) combined to ATRA and idarubicin versus standard ATRA and anthracycline-based chemotherapy (AIDA regimen) for patients with newly diagnosed, high-risk acute promyelocytic leukemia | ja |
| CAD | PDY16370 BIVV020 | 2019-001844-22 | 1b | A multicenter, Phase 1b, open label, nonrandomized, single dose study evaluating the safety, tolerability and activity of BIVV020 in adults with cold agglutinin disease | ja |
| CAD | BIVV009-04 Cadenza | 2017-003539-12 | III | A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of BIVV009 in Patients with Primary Cold Agglutinin Disease without a Recent History of Blood Transfusion | ja |
| CAD | BIVV009-03 Cardinal | 2017-003538-10 | A Pivotal, Open-Label, Multicenter Study to Assess the Efficacy and Safety of BIVV009 in Patients with Primary Cold Agglutinin Disease who have a Recent History of Blood Transfusion | ja | |
| CLL | CLL-RT1 | 2018-002492-17 | II | A Prospective, Open-Label, Multicentre Phase-II-Trial To Evaluate The Efficacy And Safety Of Zanubrutinib (BGB-3111), A BTK Inhibitor, Plus Teslelizumab (BGB-A317), A PD-1 Inhibitor, For Treatment Of Patients With Richter Transformation (CLL-RT1-Trial Of The GCLLSG) | ja |
| CLL | CLL-Register | n/a | ohne | Registry of the German CLL Study Group: Long term follow-up of patients with CLL, B-PLL, T-PLL, SLL, T/NK-LGL, HCL and Richter´s transformation | ja |
| CLL | CLLM1 | 2011-004698-98 | III | Eine multizentrische, randomisierte, doppelblinde, plazebokontrollierte Phase 3 Studie, in der parallel die Wirksamkeit und Sicherzeit von Lenalidomid (Revlimid®) als Erhaltungstherapie bei CLL-Patienten mit einem hohen Risiko eines frühen Progresses nach Erstlinienbehandlung | ja |
| CLL | CLL2-GIVe | 2015-004606-41 | II | A prospective, open-label, multicentre phase-II trial of ibrutinib plus venetoclax plus obinutuzumab in physically fit (CIRS ≤ 6 normal creatinine clearance) and unfit (CIRS > 6 & creatinine clearance ≥ 50ml/min) patients with previously untreated chronic lymphocytic leukemia (CLL) with TP53 deletion (17p-) and/or mutation | ja |
| CLL | CLL2-BIO | 2014-000590-39 | II | A prospective, open-label, multicentre phase-II trial to evaluate the efficacy and safety of a sequential regimen of bendamustine followed by ibrutinib and ofatumumab (BIO) followed by ibrutinib and afatumumab maintenance in CLL patients | ja |
| CLL | CLL13 "GAIA" | 2015-004936-36 | III | A phase 3 multicenter, randomized, prospective, open-label trial of standard chemoimmunotherapy (FCR/BR) versus rituximab plus venetoclax (RVE) versus obinutuzumab (GA101) plus venetoclax (GVE) versus obinutuzumab plus ibrutinib plus venetoclax (GIVE) in fit patients with previously untreated chronic lymphocyic leukemia (CLL) without del(17p) or TP53 mutation | ja |
| CLL | CLL12 | 2013-003211-22 | III | A placebo-controlled, double-blind, randomized, multicenter phase III trial of Ibrutinib vs. deferred treatment in previously untreated Binet stage A CLL with risk of early disease progression | ja |
| NHL | Alternative C | 2018-004038-13 | II | A Prospective Multicenter Phase 2 Study of the Chemotherapy-Free. Combination of the Intravenous Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Copanlisib in Combination with Obinutuzumab in Patients with previously Untreated Follicular Lymphoma (FL) and a High Tumor Burden | ja |
| CLL | ACP-196 D8220C00008 (Astra Zeneca) | ohne | III b | A Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib (ACP-196) in Subjects with Chronic Lymphocytic Leukemia | ja |
| CML | PONS | 2016-000618-30 | II | Phase 2 Clinical Trial with Ponatinib as a Second Line Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to prior First Line Tyrosine Kinase Inhibitor Treatment | ja |
| CML | Ponderosa | IV | Beobachtungsstudie mit Patienten mit CML in allen Phasen, die mit Ponatinib (Iclusig ®) in jeglicher Dosierung behandelt werden | ja | |
| CML | NAUT CAMN107ADE22T | 2015-004998-33 | Multicenter prospective trial after first unsuccessful treatment discontinuation in chronic myeloid leukemia estimating the efficacy of nilotinib in inducing the persistence of molecular remission after stopping TKI a 2nd time | ja | |
| CML | Fascination | 2018-002256-33 | II | Frontline Asciminib combination in chronic phase CML | ja |
| CML | ENDURE CML-IX | 2016-001030-94 | II | Randomisierte Phase II Studie zur Untersuchung der Sicherheit und Effektivität einer Therapie mit pegyliertem Prolin-Interferon alpha 2b (AOP2014) zur Erhaltung einer tiefen molekularen Remission bei Patienten mit chronischer myeloischer Leukämie – eine randomisierte, multizentrische Phase-II-Studie mit anschließender Nachbeobachtungsphase außerhalb der Studie | ja |
| CML | Dastop-2 MED3_201701 | 2016-004106-34 | II | Persistance of major molecular remission in chronic myeloid leukemia after a second stop of TKI treatment in patients who failed an initial stop attempt: a multicenter prospective trail | ja |
| CML | DasaHIT | 2015-003502-16 | III | Treatment optimization for patients with chronic myeloid leukemia (CML) with treatment naïve disease (1st line) and patients with resistance or intolerance against alternative ABL-kinase inhibitors (≥2nd line) | ja |
| CML | CAMN107ADE20 NILO-deep-R | 2015-000968-34 | IV | A Phase IV single arm, multicenter, open-label study assessing deep molecular response in adult patients with newly diagnosed Philadelphia chromosome positive CML in chronic phase after two years of treatment with nilotinib 300 mg BID | ja |
| HD | Targeted BEACOPP | 2011-005082-21 | II | Targeted BEACOPP variants in patients with newly diagnosed advanced classical Hodgkin Lymphoma | ja |
| HD | NIVAHL | 2016-002626-37 | II | NIVAHL - Nivolumab and AVD in early-stage unfavorable classical Hodgkin lymphoma: A GHSG randomized, multicenter phase II trial | ja |
| HD | HD-R3i Ever-DHAP | 2010-021086-73 | I/II | A prospective, randomized, placebo-controlled, international, multicenter phase I/II trial of RAD001 (everolimus) in combination with DHAP as induction therapy in patients with relapsed or refractory Hodgkin Lymphoma | ja |
| HD | HD21 | 2014-005130-55 | III | Treatment optimization trial in the first-line treatment of advanced stage Hodgkin lymphoma; comparison of 6 cycles of escalated BEACOPP with 6 cycles of BrECADD | ja |
| HD | HD18 | 2007-003187-22 | ohne | Therapieoptimierungsstudie in der Primärtherapie des fortgeschrittenen Hodgkin Lymphoms: Therapiestratifizierung mittels FDG-PET | ja |
| HD | HD17 | 2007-005920-34 | III | Therapieoptimierungsstudie in der Primärtherapie des intermediären Hodgkin-Lymphoms: Therapiestratifizierung mittels FDG-PET | ja |
| HD | HD16 | 2007-004474-24 | ohne | Therapieoptimierungsstudie in der Primärtherapie des frühen Hodgkin Lymphoms: Therapiestratifizierung mittels FDG-PET | ja |
| HD | GHSG-AFM13 | 2014-004036-19 | II | GHSG-AFM13: An open-label, randomized, multicenter phase II trial with AFM13 in patients with relapsed or refractory Hodgkin Lymphoma (HL). | ja |
| ITP | ARGX-113-1803 | 2019-002100-41 | III | A Long-Term, Single-Arm, Open-Label, Multicenter, Phase III Follow-On Trial to Evaluate Safety and Efficacy of Intravenous Efgartigimod (ARGX-113) in Adult Patients with Primary Immune Thrombocytopenia | ja |
| ITP | ARGX-113-1801 | 2019-002100-41 | III | A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Efgartigimod (ARGX-113) 10 mg/kg Intravenous in Adult Patients with Primary Immune Thrombocytopenia | ja |
| MCL | TRIANGLE | 2014-001363-12 | III | Autologous Transplantation after a Rituximab/Ibrutinib/Ara-C containing induction in generalized mantle cell lymphoma - a European MCL network study | ja |
| MCL | R2 elderly | 2012-002542-20 | III | Efficacy of alternating immunochemotherapy consisting of R-CHOP + R-HAD versus R-CHOP alone, followed by maintenance therapy consisting of additional lenalidomide with rituximab versus rituximab alone for older patients with mantle cell lymphoma | ja |
| MCL | PCYC-1143-CA | 2017-000129-12 | III | Phase 3 Study of Ibrutnib in Combination with Venetoklax in Subjects with Mantle Cell Lymphoma | ja |
| MCL | PCI-32765CAN3001 | 2012-004225-24 | IIIb | A phase 3b, multicenter, open-label, PCI-32765 (Ibrutinib) long-term extension study | ja |
| MCL | INCB 50465-205 CITADEL-205 | 2017-003148-19 | II | A Phase 2, Open-Label, 2-Cohort, Multicenter Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor (CITADEL-205) | ja |
| MM | GMMG-HD6 | 2014-003079-40 | III | Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide plus Lowdose | ja |
| MM | CC-4047-MM-007 | 2014-000268-17 | III | A phase 3, multicenter, randomized, open-label study to compare the efficacy and safety of pomalidomide, bortezomib and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in subjects with relapsed or refractory multiple myeloma | ja |
| MM | C16019 "Tourmaline" | 2013-002076-41 | III | Placebokontrollierte, randomisierte Phase III-Doppelblindstudie zur oralen Erhaltungstherapie mit Ixazomib Citrat (MLN9708) im Anschluss an eine autologe Stammzelltransplantation bei Patienten mit Multiplem Myelom | ja |
| MM | 54767414MMY2065LYNX | 2018-004185-34 | II | A Phase 2 Study of Daratumumab Subcutaneous (Dara-SC) Administration in Combination with Carfilzomib and Dexamethasone (DKd) Compared with Carfilzomib and Dexamethasone (Kd) in Participants with Multiple Myeloma who have been Previously Treated with Daratumumab Intravenous (Dara-IV) to Evaluate Daratumumab Retreatment | ja |
| MM | GMMG-CONCEPT | 2016-000432-17 | II | Eine klinische Phase II Studie zur Induktions-, Konsolidierungs- und Erhaltungstherapie mit Isatuximab, Carfilzomib, Lenalidomid und Dexamethason (I-KRd) in der Primärtherapie des Hochrisikomyeloms | ja |
| MPN | SRA-MMB-301 | 2019-000583-18 | III | A Randomized, Double-Blind, Phase 3 Study to Evaluate the Activity of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic, Anemic Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera (PV) Myelofibrosis, or Post Essential Thrombocythemia (ET) Myelofibrosis who were Previously Treated with JAK Inhibitor Therapy | ja |
| MPN | SAL-MPN-Register | ohne | ohne | SAL-MPN-Register und Biomaterieldatenbank der Studienallianz Leukämie (SAL) | ja |
| MPN | Ruxo-BEAT, 12-181 | 2013-002132-25 | IIB | Ruxolitinib versus Best Available Therapy in patients with high-risk polycythemia vera or high-risk essential thrombocythemia - The Ruxo-BEAT Trial | ja |
| MPN | MPNSG 02-12 POMINC | 2012-002431-29 | Ib/II | A Phase-Ib/II Study of Ruxolitinib and Pomalidomide Combination Therapy in Patients with Primary and Secondary Myelofibrosis | ja |
| MPN | MMM 02 study CTC12729 | 2014-005210-28 | II | Ruxolitinib versus allogenic stem cell transplantation für patients with myelofibrosis according to donor availability: A prospective phase II (MMM 02study) | ja |
| MPN | IMG-7289-CTP-201 | 2019-003659-13 | II | A Phase 2 Multi-Center, Open Label Study to Assess the Safety, Efficacy and Pharmacodynamics of IMG-7289 in Patients with Essential Thrombocythemia | ja |
| MPN | IMG-7289-CTP-102 | 2018-003811-23 | I/II | A Multi-Center, Open Label Study to Assess the Safety, Steady-State Pharmacokinetics and Pharmacodynamics of IMG-7289 in Patients with Myelofibrosis | ja |
| MPN | CINC424BDE12 PaVe-NIS | ohne | ohne | PaVe - Eine prospektive, nicht-interventionelle Studie zur JAKAVI®-Behandlung von Patienten mit Polycythaemia vera | ja |
| MPN | Besremi-PASS EUPAS29462 | ohne | IIb | A Prospective, Multicentre, Non-interventional, Observational, Post-authorisation Safety Study of Ropeginterferon alfa-2b in Polycythaemia Vera Patients | ja |
| MZoL | OLYMP-1 | 2017-003149-56 | II | Phase II, single arm, multicentric, open label, non-randomized: Obinutuzumab in marginal zone lymphoma | ja |
| MZoL | Marginalzonenlymphom-Register | n/a | Nicht-interventionelles prospektives Register zu Epidemiologie und Behandlungspraxis bei Marginalzonenlymphomen | ja | |
| MZoL | INCB 50465-204 CITADEL-204 | 2017-000970-12 | II | A Phase 2, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects With Relapsed or Refractory Marginal Zone Lymphome With or Without Prior Exposure to a BTK Inhibitor (CITADEL-204) | ja |
| NHL agg. | SGN35-014 "ECHELON-2" | 2012-002751-42 | III | A randomized, double-blind, placebo-controlled, phase 3 study of CH-P and brentuximab vedotin versus CHOP in the front-line treatment of patients with CD30‑positive mature T-cell lymphomas | ja |
| NHL agg. | Ro-CHOP | 2012-001580-68 | III | Phase 3 multi-center randomized study to compare efficacy and safety of Romidepsin-CHOP (Ro-CHOP) versus CHOP in patients with previously untreated peripheral T-cell lymphoma | ja |
| NHL agg. | PTLD-2 | 2013-004479-11 | II | Risk-stratified sequential treatment of post-transplant lymphoproliferative desease with 4 courses of Rituximab SC followed by 4 courses of RituximabSC, 4 courses of Rituximab SC combined with CHOP-21 or 4 courses of Rituximab SC combined with alternating CHOP-21 and DHAOx: The PTLD-2 trial | ja |
| NHL agg. | KTE-C19-101 ZUMA-1 | 2015-005007-86 | I/II | A Phase 1-2 Multicenter Study Evaluating the Safety and Efficacy of KTE-C19 in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL) (ZUMA1) | ja |
| NHL agg. | ImbruVeRCHOP | 2015-003429-32 | ohne | Ibrutinib, Bortezomib s.c., Rituximab, CHOP for the treatment of elderly patients (age 61-80 years) with CD20+ diffuse large B-cell lymphoma, IPI ≥ 2 | ja |
| NHL agg. | IELSG-37 | III | A randomized, open-label, multicentre, two-arm phase III comparative study assessing the role of mediastinal radiotherapy after Rituximab containing chemotherapy regimens to patients with newly diagnosed Primary Mediastinal Large B-Cell Lymphoma (PMLBCL) | ja | |
| NHL agg. | GOAL / ETN-1 | 2014-004780-21 | II | Rescue treatment with the monoclonal anti CD20-antibody Obinutuzumab (GA101) in combination with Pixantrone for the treatment of patients with relapsed Aggressive B-cell Lymphoma | ja |
| NHL agg. | GO39942 Polarix | 2017-002023-21 | III | A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Polatuzumab vedotin in Combination with Rituximab and CHP (R-CHP) versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma | ja |
| NHL agg. | MB-CART2019.1 M-2018-331 | 2018-001253-27 | I/II | A Phase I/II safety, dose finding and feasibility trial of MB-CART2019.1 in patients with relapsed or refractory CD20 and CD19 positive B-NHL | ja |
| NHL agg. | DSHNHL 2015-1 NIVEAU | 2016-002272-27 | ohne | Improvement of Outcome in Elderly Patients or Patients not eligible for high-dose chemotherapy with Aggressive Non-Hodgkin Lymphoma in first Relapse or Progression by adding Nivolumab to Gemcitabine, Oxaliplatin plus Rituximab in case of CD20+ Disease | ja |
| NHL ind. | ML29941 GAZAI | 2016-002059-89 | ohne | Therapy of Nodal Follicular Non-Hodgkin Lymphoma (WHO grade 1/2) in Clinical Stage I/II using Response Adapted Involved Site Radiotherapy in Combination with Gazyvaro | ja |
| NHL ind. | HOVON 110 FL ReBeL Study | 2011-000097-56 | I/II | A randomized phase I/II trial of lenalidomide and rituximab with or without bendamustine in patients ≥ 18 years with relapsed follicular lymphoma. | ja |
| NHL ind. | ALTERNATIVE | 2014-005164-15 | II | A Prospective Multicenter Phase 2 Study of the Chemotherapy-free Combination of the Bruton´s Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib) in Combination with Obinutuzumab (GA 101) in Patients with Previously Untreated Follicular Lymphoma (FL) and a High Tumor Burden | ja |
| NHL ind. | GABe 2016 | 2016-000755-27 | III | First line therapy of advanced stage follicular lymphoma in patients not eligible for standard immunochemotherapy. Prospective randomized comparison of single agent GA101 versus GA101 plus bendamustine followed by GA101 in medically non-fit patients | ja |
| NHL ind. | BO21223 "Gallium" | 2010-024132-41 | III | A multicenter, Phase III, open-label, randomized study in previously untreated patients with advanced indolent non-hodgkin’s lymphoma comparing GA101 (RO5072759) plus chemotherapy with rituximab plus chemotherapy followed by GA101 or rituximab maintenance therapy in responders | ja |
| PNH | CLNP023X2201 | 2017-000888-33 | ohne | An open label, single arm, multiple dose study to assess efficacy, safety, pharmacokinetics and pharmacodynamics of LNP023 when administered in addition to Standard of Care (SoC) in Patients with paroxysmal nocturnal hemoglobinuria (PNH) with signs of active hemolysis | ja |
| PNH | BP39144 "Composer" | 2016-002128-10 | I/II | An adaptive phase I/II study to assess safety, efficacy, phamacokinetics and pharmacodynamics of RO7112689 in healthy volunteers and patients with paroxysmal nocturnal hemoglobinuria (PNH) | ja |
| PNH | APL2-307 | 2019-001106-23 | III | An Open Label, Non-Randomized, Multi-Center Extension Study to Evaluate the Long Term Safety and Efficacy of APL-2 in the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). | ja |
| PNH | ALXN1210-PNH-201 | 2015-002674-20 | II | A Phase 2, Open-Label, Multiple Ascending-Dose Study to Evaluate the Efficacy, Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of ALXN1210 Administered Intravenously to Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) | ja |
| Waldenström | StiL-Studie NHL 7-2008 "MAINTAIN" | 2008-005859-16 | ohne | Prospektiv randomisierte Studie zur Therapieoptimierung (Primärtherapie) fortgeschrittener progredienter follikulärer und anderer niedrigmaligner sowie Mantelzell Lymphome | ja |
| Waldenström | ECWM-1 | 2013-000506-37 | III | Efficacy of first line Dexamethasone, Rituximab and Cyclophosphamide (DRC) +/- Bortezomib for patients with Waldenström´s Macroglobulinemia | ja |
| ZNS | MARTA | 2016-001628-72 | II | Multizentrische Phase II-Studie zur altersadaptierten Hochdosistherapie gefolgt von autologer Stammzelltransplantation bei fitten älteren Patienten > 65 Jahren mit primär zerebralem Lymphom | ja |
| ZNS | IELSG 32 < 65 Jahre | 2009-012432-32 | II | Randomized phase II trial on primary chemotherapy with high-dose methothrexate and high-dose cytarabine with or without Thiotepa, and with or without Rituximab, followed by brain irradiation vs. high-dose chemotherapy supported by autologous stem cells transplantation for immuno competent patients with newly diagnosed primary CNS lymphoma. Prüfplan Nr. 000643 | ja |
| ZNS | Freiburger ZNS-NHL-Hochdosisstudie | 2005-000615-99 | ohne | Therapie für Patienten mit primären Non-Hodgkin-Lymphomen des ZNS – Sequentielle Hochdosis-Chemotherapie mit autologer peripherer Blutstammzelltransplantation. Prüfplan Nr. 000465 | ja |
| ZNS / NHL | IELSG43 MATRix | 2012-000620-17 | III | High-dose chemotherapy and autologous stem cell transplant or consolidating conventional chemotherapy in primary CNS lymphoma - randomized phase III trial | ja |
©2020
Klinik für Hämatologie und Stammzelltransplantation
Menü